Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion.
BACKGROUND
The vaginal microbiota of healthy women consists of a wide variety of anaerobic and aerobic bacterial genera and species dominated by the genus Lactobacillus. The activity of lactobacilli helps to maintain the natural healthy balance of the vaginal microbiota. This role is particularly important during pregnancy because vaginal dismicrobism is one of the most important mechanisms for preterm birth and perinatal complications. In the present study, we characterized the impact of a dietary supplementation with the probiotic VSL#3, a mixture of Lactobacillus, Bifidobacterium and Streptococcus strains, on the vaginal microbiota and immunological profiles of healthy women during late pregnancy.


RESULTS
An association between the oral intake of the probiotic VSL#3 and changes in the composition of the vaginal microbiota of pregnant women was revealed by PCR-DGGE population profiling. Despite no significant changes were found in the amounts of the principal vaginal bacterial populations in women administered with VSL#3, qPCR results suggested a potential role of the probiotic product in counteracting the decrease of Bifidobacterium and the increase of Atopobium, that occurred in control women during late pregnancy. The modulation of the vaginal microbiota was associated with significant changes in some vaginal cytokines. In particular, the decrease of the anti-inflammatory cytokines IL-4 and IL-10 was observed only in control women but not in women supplemented with VSL#3. In addition, the probiotic consumption induced the decrease of the pro-inflammatory chemokine Eotaxin, suggesting a potential anti-inflammatory effect on the vaginal immunity.


CONCLUSIONS
Dietary supplementation with the probiotic VSL#3 during the last trimester of pregnancy was associated to a modulation of the vaginal microbiota and cytokine secretion, with potential implications in preventing preterm birth.


BACKGROUND
ClinicalTrials.gov NCT01367470.
Department of Pharmaceutical Sciences, University of Bologna, Bologna, Italy. b.vitali@unibo.it
Beatrice
B
Vitali
Federica
F
Cruciani
Maria Elisabetta
ME
Baldassarre
Teresa
T
Capursi
Enzo
E
Spisni
Maria Chiara
MC
Valerii
Marco
M
Candela
Silvia
S
Turroni
Patrizia
P
Brigidi
D000328:Adult; D058448:Biota; D016207:Cytokines / Q000378:metabolism*; D058645:Denaturing Gradient Gel Electrophoresis; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D054892:Metagenome; D010865:Pilot Projects; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D019936:Probiotics / Q000008:administration & dosage*; D014621:Vagina / Q000276:immunology* / Q000382:microbiology*; D055815:Young Adult
D016207:Cytokines